caa a22 4500 445310642 CHVBK 20180317142628.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s00404-011-1951-5 doi (NATIONALLICENCE)springer-10.1007/s00404-011-1951-5 A randomized trial of ovulation induction with two different doses of Letrozole in women with PCOS [Elektronische Daten] [Fatemeh Ramezanzadeh, Roya Nasiri, Mohammad Sarafraz Yazdi, Maryam Baghrei] Objective: To compare the effects of either a 5 or 7.5mg daily dose of Letrozole in PCOS women undergoing ovulation induction and timed intercourse. Design: Prospective randomized trial. Setting: Academic infertility care center. Patients: Sixty-seven PCOS patients with infertility. Interventions: Patients were randomly divided into two groups and treated with either 5mg/day (30 patients, group 1) or 7.5mg/day (37 patients, group 2) Letrozole for 5days starting from day 3 of the menstrual cycle. When the leading follicle reached 18mm in diameter, ovulation was triggered by an injection of HCG and timed intercourse was advised thereafter. Main outcome measures: The primary outcome measures were the number of follicles and days to reach mature follicle and the secondary endpoints were endometrial thickness, day 7 testosterone level, ovulation and pregnancy rates. Results: The mean age, BMI, duration of infertility and basal hormone levels in both groups were similar. There was no significant difference in the endometrial thickness (7.87±1.67 vs 7.16±2.04), the number of intermediate (0.83±0.75 vs 0.62±0.76) and mature follicles (1.13±1.11 vs 1.22±1.03) on days 12-14 between group 1 and 2, respectively. The days to reach mature follicle were similar in both groups (12.8±1.36 vs 12.6±1.22). Also there was no significant difference in the day 7 testosterone level and day 21 progesterone level between the two. Ovulation occurred in 90 and 89.2% of patients in group 1 and 2, respectively without a statistically significant difference. The pregnancy rate per first ovulatory cycle was 25.8% in group 1 and 21.2% in group 2 without significant difference. No OHSS was observed in either group. Conclusion(s): The results of this study did not show any advantage to the use of 7.5mg/day over 5mg/day dose of Letrozole as the first line treatment for induction of ovulation in women with PCOS. Springer-Verlag, 2011 Polycystic ovary syndrome nationallicence Letrozole nationallicence Ovulation nationallicence Pregnancy nationallicence Follicle nationallicence Ramezanzadeh Fatemeh Vali-E-asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran aut Nasiri Roya Department of Obstetrics and Gynecology, Mashhad Branch, Islamic Azad University, Mashhad, Iran aut Sarafraz Yazdi Mohammad Department of Internal Medicine - Endocrine Unit, Mashhad Branch, Islamic Azad University, Mashhad, Iran aut Baghrei Maryam Vali-E-asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran aut Archives of Gynecology and Obstetrics Springer-Verlag 284/4(2011-10-01), 1029-1034 0932-0067 284:4<1029 2011 284 404 https://doi.org/10.1007/s00404-011-1951-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00404-011-1951-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ramezanzadeh Fatemeh Vali-E-asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran aut NATIONALLICENCE 700 1- Nasiri Roya Department of Obstetrics and Gynecology, Mashhad Branch, Islamic Azad University, Mashhad, Iran aut NATIONALLICENCE 700 1- Sarafraz Yazdi Mohammad Department of Internal Medicine - Endocrine Unit, Mashhad Branch, Islamic Azad University, Mashhad, Iran aut NATIONALLICENCE 700 1- Baghrei Maryam Vali-E-asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran aut NATIONALLICENCE 773 0- Archives of Gynecology and Obstetrics Springer-Verlag 284/4(2011-10-01), 1029-1034 0932-0067 284:4<1029 2011 284 404 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer